pH-dependent drug-drug interactions for weak base drugs: Potential implications for new drug development

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 2, 2014, Pages 266-277

  Zhang, L ^a   Wu, F ^a,b   Lee, S C ^a   Zhao, H ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ATAZANAVIR; AXITINIB; BOSUTINIB; CRIZOTINIB; DABIGATRAN; DARUNAVIR; DASATINIB; DRONEDARONE; ERLOTINIB; GEFITINIB; GEMIFLOXACIN; NILOTINIB; POSACONAZOLE; PRASUGREL; RILPIVIRINE; SAXAGLIPTIN; SORAFENIB; TADALAFIL; TAPENTADOL; TELITHROMYCIN; VARDENAFIL;

ALKALINITY; ARTICLE; CONCEPTUAL FRAMEWORK; DRUG INFORMATION; DRUG RESEARCH; DRUG SOLUBILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; PH; PRIORITY JOURNAL; STOMACH ACID;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; DRUG INTERACTIONS; DRUG LABELING; GASTRIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84904857990     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.87     Document Type: Article

References (37)

1. Haruma, K. et al. Effect of age and Helicobacter pylori infection on gastric acid secretion. J. Gastroenterol. Hepatol. 15, 277-283 (2000 (Pubitemid 30190741)
2. Mooiman, K.D. et al. The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-Trifluoromethyl-coumarin, midazolam and docetaxel. J. Pharm. Pharmacol. 66, 865-874 (2014
3. Hermann, R. & von Richter, O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med. 78, 1458-1477 (2012
4. Ware, J.A. et al. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: Bench to bedside investigation of ph-dependent solubility. Mol. Pharm. 10, 4074-4081 (2013
5. Hanley, M.J., Cancalon, P., Widmer, W.W. & Greenblatt, D.J. The effect of grapefruit juice on drug disposition. Expert Opin. Drug Metab. Toxicol. 7, 267-286 (2011
6. Chin, T.W., Loeb, M. & Fong, I.W. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob. Agents Chemother. 39, 1671-1675 (1995
7. Pepcid [package insert]. http: //www.accessdata.fda.gov/drugsatfda-docs/ label/2011/019462s037lbl.pdf. Accessed 18 May 2013
8. Axid [package insert]. http: //www.accessdata.fda.gov/drugsatfda-docs/ label/2005/019508s033lbl.pdf. Accessed 18 May 2013
9. Boyce, M., David, O., Darwin, K., Mitchell, T., Johnston, A. & Warrington, S. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Aliment. Pharmacol. Ther. 36, 181-189 (2012
10. Prilosec [package insert]. http: //www.accessdata.fda.gov/drugsatfda- docs/ label/2013/019810s097, 022056s013lbl.pdf. Accessed 15 June 2013
11. Drugs@FDA, Clinical Pharmacology Review of Esomeprazole NDA 21-153. http: //www.accessdata.fda.gov/drugsatfda-docs/nda/2001/21154-Nexium-biopharmr-P1. pdf. Accessed 18 May 2013
12. Müssig, S., Witzel, L., Lühmann, R. & Schneider, A. Morning and evening administration of pantoprazole: A study to compare the effect on 24-hour intragastric pH. Eur. J. Gastroenterol. Hepatol. 9, 599-602 (1997 (Pubitemid 27267692)
13. Smelick, G.S. et al. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol. Pharm. 10, 4055-4062 (2013
14. van Lunzen, J., Liess, H., Arastéh, K., Walli, R., Daut, B. & Schürmann, D. Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy. HIV Med. 8, 220-225 (2007 (Pubitemid 46691692)
15. Hurwitz, A. Antacid therapy and drug kinetics. Clin. Pharmacokinet. 2, 269-280 (1977 (Pubitemid 8164679)
16. G ugler, R. & Allgayer, H. Effects of antacids on the clinical pharmacokinetics of drugs. An update. Clin. Pharmacokinet. 18, 210-219 (1990 (Pubitemid 20109454)
17. Humphries, T.J. & Merritt, G.J. Review pages: Drug interactions with agents used to treat acid-related diseases. Aliment. Pharmacol. Ther. 13 (suppl. 3), 18-26 (1999 (Pubitemid 29389408)
18. Ogawa, R. & Echizen, H. Clinically significant drug interactions with antacids: An update. Drugs 71, 1839-1864 (2011
19. Neuvonen, P.J. & Kivisto, K.T. DEnhancement of drug absorption by antacids. An unrecognised drug interaction Clin Pharmacokinet. 27, 120-128 (1994 (Pubitemid 24244852)
20. Budha, N.R. et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: Is pH-dependent solubility the Achilles heel of targeted therapy? Clin. Pharmacol. Ther. 92, 203-213 (2012
21. Duong, S. & Leung, M. Should the concomitant use of erlotinib and acidreducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents. J. Oncol. Pharm. Pract. 17, 448-452 (2011
22. ALBERT, A. Avidity of terramycin and aureomycin for metallic cations. Nature 172, 201 (1953
23. Neuvonen, P.J., Gothoni, G., Hackman, R. & Björksten, K. Interference of iron with the absorption of tetracyclines in man. Br. Med. J. 4, 532-534 (1970
24. Ogilvie, B.W. et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: Implications for coadministration with clopidogrel. Drug Metab. Dispos. 39, 2020-2033 (2011
25. Ito, S. et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J. Pharmacol. Exp. Ther. 340, 393-403 (2012
26. Martínez, C. et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin. Pharmacol. Ther. 65, 369-376 (1999 (Pubitemid 29196538)
27. Yin, O.Q. et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J. Clin. Pharmacol. 50, 960-967 (2010
28. US Food and Drug Administration. Guidance for Industry. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. http: //www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ucm070246.pdf. Accessed 12 December 2013
29. Prevacid [package insert]. http: //www.accessdata.fda.gov/drugsatfda- docs/ label/2012/020406s078-021428s025lbl.pdf. Accessed 28 June 2013
30. Protonix [package insert]. http: //www.accessdata.fda.gov/ drugsatfda-docs/label/2012/020987s043, 022020s006lbl.pdf. Accessed 28 June 2013
31. Li, X.Q., Andersson, T.B., Ahlström, M. & Weidolf, L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dispos. 32, 821-827 (2004 (Pubitemid 38955611)
32. Meyer, U.A. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur. J. Gastroenterol. Hepatol. 8 (suppl. 1), S21-S25 (1996
33. Vanderhoff, B.T. & Tahboub, R.M. Proton pump inhibitors: An update. Am. Fam. Physician 66, 273-280 (2002 (Pubitemid 34810080)
34. Ogawa, R. & Echizen, H. Drug-drug interaction profiles of proton pump inhibitors. Clin. Pharmacokinet. 49, 509-533 (2010
35. Wittwer, M.B. et al. Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J. Med. Chem. 56, 781-795 (2013
36. Maton, P.N. & Burton, M.E. Antacids revisited: A review of their clinical pharmacology and recommended therapeutic use. Drugs 57, 855-870 (1999 (Pubitemid 29313197)
37. US Food and Drug Administration. Guidance for Industry. Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http: //www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed 10 July 2013.